Cardiovascular and renal outcomes with empagliflozin in heart failure
- Packer M.
- Anker S. D.
- Butler J.
- Filippatos G.
- Pocock S. J.
- Carson P.
- Januzzi J.
- Verma S.
- Tsutsui H.
- Brueckmann M.
- Jamal W.
- Kimura K.
- Schnee J.
- Zeller C.
- Cotton D.
- Bocchi E.
- Bohm M.
- Choi D. -J.
- Chopra V.
- Chuquiure E.
- Giannetti N.
- Janssens S.
- Zhang J.
- Gonzalez Juanatey J. R.
- Kaul S.
- Brunner-La Rocca H. -P.
- Merkely B.
- Nicholls S. J.
- Perrone S.
- Pina I.
- Ponikowski P.
- Sattar N.
- Senni M.
- Seronde M. -F.
- Spinar J.
- Squire I.
- Taddei S.
- Wanner C.
- Zannad F.
DOIAbstract
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS During a median of 16 months, a primar...
Add to ORKG